ʵϰһ ҽѧÎÄÏ×Ö÷Ìâ±êÒý
ʵϰѧʱ:2ѧʱ
Ò»¡¢ÊµÏ°Ä¿µÄ
1.Á˽âҽѧÎÄÏ×Ö÷Ìâ±êÒýµÄ»ù±¾ÖªÊ¶ £¬ÊìϤÖ÷Ìâ±êÒýµÄ·½·¨¡£ 2.ÕÆÎÕÖÐÍâÎÄÎÄÏ×¼ìË÷ʱÖ÷Ìâ´ÊÓ븱Ö÷Ìâ´ÊµÄÆ¥Åä¡£ ¶þ¡¢Ò½Ñ§ÎÄÏ×±êÒýÄÚÈÝ
1£®Ö÷Ìâ±êÒý¶¨Ò壺
ͨ¹ýÎÄÏ×£¨Ïà¹Ø¿ÎÌ⣩µÄ·ÖÎö£¬ÌáÁ¶³öÖ÷Ìâ¸ÅÄîת»»³ÉÖ÷Ìâ´Ê¡¢¹Ø¼ü´ÊµÈ¼ìË÷ÓïÑÔ£¬²¢ÒÔ´Ë×÷ΪÎÄÏ×±êʶ¡£ÕâÒ»¹ý³Ì¾Í³ÆΪÖ÷Ìâ±êÒý¡£
¹Ø¼ü´Ê£ºÊÇ´ÓÎÄÏ׵ıêÌâ¡¢ÕªÒªºÍÕýÎÄÖгéÈ¡³öÀ´£¬Äܱí´ïÎÄÏ×ʵÖÊÄÚÈݵġ¢¹Ø¼üÐÔµÄרҵÃû´ÊÊõÓï¡££¨Î´×÷¹æ·¶£¬ÌرðÊÊÓÚ¼ÆËã»ú¼ìË÷¡££©
Ö÷Ìâ´Ê£º¾¹ý¹æ·¶»¯´¦Àí£¨ÓÐרÃŵÄÖ÷Ìâ´Ê±í£©µÄ¾ßÓÐʵÖÊÐÔÒâÒåµÄ´Ê»ò´Ê×é¡£ ¢ÅÖ÷Òª±êÒý´Ê£¨Mjme£© Major MeSH£º¶ÔÎÄÏ׺ËÐÄÖ÷Ìâ¸ÅÄîµÄ±êʶ¡£¼´Ö÷ÒªÖ÷Ìâ´ÊµÄ±êÒý£¬ÊÇһƪÎÄÏ×ÖÐÖ÷ÒªÂÛÊöµÄÄÚÈÝ£¬(Ëùռƪ·ù½Ï¶à)¡£ËüÃÇ¿ÉÄÜÊÇʵÑéÑо¿µÄÄ¿µÄ¡¢½á¹û£»ÁÙ´²¼²²¡µÄÔ¤·À¡¢Õï¶Ï¡¢ÖÎÁƵÈÖ÷ÒªÊֶΡ¢·½·¨ºÍ´´Ðµȡ£ÔÚMEDLINE¡¢CBMϵͳÖÐÓüÓȨ·ûºÅ¡°©~¡±±íʾ¡£
¢Æ´ÎÒª±êÒý´Ê£¨Mime£© Minor MeSH £ºÖ¸¶ÔÎÄÏ×´ÎÖصã¸ÅÄîµÄ±êʶ¡£ÈçʵÑ鶯ÎïÖÖÀà¡¢ÈËÀàÐÔ±ðÓëÄêÁä×éµÈ¡£ Ö÷ÒªÓë´ÎÒªµÄ¸ÅÄîÊÇÏà¶ÔÓÚijƪÌض¨ÎÄÏ׵ġ£ ¢Ç±êÒýÉî¶È
Ö¸¶ÔһƪÎÄÏ×½øÐÐÖÜÏê±êÒýµÄ³Ì¶È£¬¼´¸øÓè¸ÃÎÄÏ×¼ìË÷±êʶµÄÊýÁ¿¡£¼ìË÷±êʶÉÙ£¬³ÆΪdz±êÒý£»·´Ö®£¬ÎªÉî±êÒý¡£ÈçIM µÄ±êÒýÉî¶ÈΪ2¡«5¸ö£¬MEDLINEΪ10¶à¸ö¡£ Àý1£®CBMÖø¼×Ö¶Î
·Ö Àà ºÅ£ºR331.141; R589.9; R749.16; R749.160.4 ±ê Ì⣺Ѫ¹ÜÐÔ³Õ´ô»¼Õߺìϸ°ûÄÚ΢Á¿ÔªËصı仯 ¹Ø ¼ü ´Ê£ººìϸ°û; ΢Á¿ÔªËØ; Ѫ¹ÜÐÔ³Õ´ô
Ö÷ Ìâ ´Ê£º³Õ´ô, Ѫ¹ÜÐÔ/*´úл; ³Õ´ô, Ѫ¹ÜÐÔ/Õï¶Ï; ºÛÁ¿ÔªËØ/*´úл; ºìϸ°û/*´úл ÌØ Õ÷ ´Ê£º¶Ô±ÈÑо¿; ÈËÀà Àý2£®MEDLINEÖø¼×Ö¶Î
TI: Preservation of the lima pedicle after cardiac surgery in left upper lobectomy.
MESH: *Carcinoma,-Non-Small-Cell-Lung-surgery; *Coronary-Artery-Bypass-methods;
*Internal-Mammary-Coronary-Artery-Anastomosis; *Lung-Neoplasms-surgery; *Pneumonectomy-methods
1
MESH: Aged-; Aged,-80-and-over;
Carcinoma,-Non-Small-Cell-Lung-complications;
Carcinoma,-Non-Small-Cell-Lung-pathology; Coronary-Stenosis-complications; Coronary-Stenosis-diagnosis; Coronary-Stenosis-surgery; Follow-Up-Studies; Lung-Neoplasms-complications; Lung-Neoplasms-pathology;
Preservation,-Biological; Risk-Assessment; Thoracotomy-; Treatment-Outcome TG: Human; Male 2£®Ö÷Ìâ±êÒýµÄ²½Öè
£¨1£©¶ÔÎÄÏ×»ò¿ÎÌâ½øÐÐÉîÈëϸÖµķÖÎö£¨Ä¿µÄ¡¢ÒªÇó¡¢Ïà¹ØÐÅÏ¢µÈ£© £¨2£©ÌáÁ¶Ö÷Ìâ¸ÅÄÓÃרҵÊõÓ £¨3£©×ª»»ÎªÏàÓ¦µÄ¹Ø¼ü´Ê»òÖ÷Ìâ´Ê 3£®±êÒýʾÀý£º
£¨1£© ΢Á¿ÔªËصķÖÎö
·ÖÎö£ºÒ»¸öÖ÷Ìâ¸ÅÄ¼´Î¢Á¿ÔªËØ(trace element) £¬¾ßÌå·ÖÎöӦΪ΢Á¿ÔªËØ·ÖÎö·½ÃæµÄÎÄÏס£
±êÒý£ººÛÁ¿ÔªËØ£¨trace elements£©/·ÖÎö£¨analysis£© £¨2£© °¢Ë¾Æ¥ÁÖÓÕ·¢Ïø´
·ÖÎö£ºÁ½¸öÖ÷Ìâ¸ÅÄ¼´°¢Ë¾Æ¥ÁÖ(aspirin)ºÍÏø´(asthma)£¬¾ßÌå·ÖÎö£¬Ó¦Îª°¢Ë¾Æ¥ÁÖ/¸±×÷Ó÷½ÃæµÄÎÄÏס¢Ïø´/»¯Ñ§ÓÕµ¼·½ÃæµÄÎÄÏס£
±êÒý£º °¢Ë¾Æ¥ÁÖ£¨aspirin£©/¸±×÷Óã¨adverse effects£©
Ïø´£¨asthma£©/»¯Ñ§ÓÕµ¼£¨chemically induced£©
£¨3£© ÂýÐÔÉöË¥½ßÒýÆðƶѪ
·ÖÎö£ºÁ½¸öÖ÷Ìâ¸ÅÄ¼´ÂýÐÔÉöË¥½ß(chronic kidney failure)ºÍƶѪ(anemia)£¬¾ßÌå·ÖÎö£¬Ó¦ÎªÂýÐÔÉöË¥½ß²¢·¢Ö¢·½ÃæµÄÎÄÏס¢Æ¶Ñª²¡Òòѧ·½ÃæµÄÎÄÏס£
±êÒý£ºÉöË¥½ß,ÂýÐÔ (kidney failure,chronic)/²¢·¢Ö¢£¨complications£© ƶѪ£¨anemia£©/²¡Òòѧ£¨etiology£©
Èý¡¢ÊµÏ°Ìâ
1£® ÍâÔ´ÐÔ¸Æ×èÖͼÁ·½·¨µÄ×ÛÊö 8£® ÓÄÃÅÂݸ˾úÓëÃÅÂö¸ßѹÏà¹ØÐÔÑо¿ 2£® ¼±ÐÔÉöË¥½ßµÄÖÎÁÆ 9£® С¶ù²¡¶¾ÐÔÐļ¡Ñ×Ѫ½¬ÄÚƤËر仯 3£® ѪҺÖдÙÐÔÏÙ¼¤ËصIJⶨ 10£® ¶ùͯ½áºË²¡¿¹ðìÒ©ÎïµÄ¸±×÷Óà 4£® °×ÄÚÕÏÕª³ýÊõ 11£® ¸ÆÔ¤·ÀÈÑÉï¸ßѪѹ×ÛºÏÕ÷µÄÑо¿ 5£® ¹ÇËèÒÆÖ²ÖÎÁÆ°×Ѫ²¡ 12£® °×Ѫ²¡Ï¸°ûµòÍöµÄ»ùÒò±í´ïµ÷¿Ø 6£® °¢Ë¹Æ¥ÁÖ¶ÔÐļ¡¹£ÈûµÄÈÜѪ˨×÷Óà 13£® ÈÈÐݵ°°×¶ÔÐļ¡µÄ±£»¤×÷Óà 7£® ¼±ÐÔÁÜ°Íϸ°ûÐÔ°×Ѫ²¡µÄÕï¶Ï 14£® ϸ°ûÕ³¸½·Ö×ÓÓëÐļ¡È±ÑªÔÙ¹àËðÉË 15£® ¶ñÐÔÖ×ÁöÍØÆËÒ칹ø²â¶¨ 17£® ÈÈÐݿ˵°70ÔÚʳ¹ÜÁÛ°©Öеıí´ï 16£® ѪÇåÁ×ËáÆÏÌÑÌÇÒ칹ø»îÐԲⶨ 18£® Ôöֳϸ°ûºË¿¹ÔÔÚÂѳ²°©Öбí´ï
2
ËÄ¡¢ÊµÏ°±¨¸æ
3
4